Liam G Heaney1, John Busby1, Peter Bradding2, Rekha Chaudhuri3, Adel H Mansur4, Robert Niven5, Ian D Pavord6, John T Lindsay7, Richard W Costello8. 1. 1 Queen's University Belfast, Belfast, United Kingdom. 2. 2 University of Leicester, Leicester, United Kingdom. 3. 3 Gartnavel General Hospital and University of Glasgow, Glasgow, Scotland. 4. 4 University of Birmingham, Birmingham, United Kingdom. 5. 5 The University of Manchester, Manchester, United Kingdom. 6. 6 University of Oxford, Oxford, United Kingdom. 7. 7 Belfast Health and Social Care Trust, Belfast, United Kingdom; and. 8. 8 Royal College of Surgeons in Ireland, Dublin, Ireland.
Abstract
RATIONALE: Poor adherence is common in difficult-to-control asthma. Distinguishing patients with difficult-to-control asthma who respond to inhaled corticosteroids (ICS) from refractory asthma is an important clinical challenge. OBJECTIVES: Suppression of fractional exhaled nitric oxide (FeNO) with directly observed ICS therapy over 7 days can identify nonadherence to ICS treatment in difficult-to-control asthma. We examined the feasibility and utility of FeNO suppression testing in routine clinical care within UK severe asthma centers using remote monitoring technologies. METHODS: A web-based interface with integrated remote monitoring technology was developed to deliver FeNO suppression testing. We examined the utility of FeNO suppression testing to demonstrate ICS responsiveness and clinical benefit on electronically monitored treatment with standard high-dose ICS and long-acting β2-agonist treatment. MEASUREMENTS AND MAIN RESULTS: Clinical response was assessed using the Asthma Control Questionnaire-5, spirometry, and biomarker measurements (FeNO and peripheral blood eosinophil count). Of 250 subjects, 201 completed the test with 130 positive suppression tests. Compared with a negative suppression test, a positive test identified a FeNO-low population when adherent with ICS/long-acting β2-agonist (median, 26 ppb [interquartile range, 16-36 ppb] vs. 43 ppb [interquartile range, 38-73 ppb]) with significantly greater FEV1% (mean, 88.2 ± 16.4 vs. 74.1 ± 20.9; P < 0.01). Asthma Control Questionnaire-5 improved significantly in both groups (positive test: mean difference, -1.2; 95% confidence interval, -0.9 to -1.5; negative test: mean difference, -0.9; 95% confidence interval, -0.4 to -1.3). CONCLUSIONS: Remote FeNO suppression testing is an effective means of identifying nonadherence to ICS in subjects with difficult-to-control asthma and the substantial population of subjects who derive important clinical benefits from optimized ICS/long-acting β2-agonist treatment.
RATIONALE: Poor adherence is common in difficult-to-control asthma. Distinguishing patients with difficult-to-control asthma who respond to inhaled corticosteroids (ICS) from refractory asthma is an important clinical challenge. OBJECTIVES: Suppression of fractional exhaled nitric oxide (FeNO) with directly observed ICS therapy over 7 days can identify nonadherence to ICS treatment in difficult-to-control asthma. We examined the feasibility and utility of FeNO suppression testing in routine clinical care within UK severe asthma centers using remote monitoring technologies. METHODS: A web-based interface with integrated remote monitoring technology was developed to deliver FeNO suppression testing. We examined the utility of FeNO suppression testing to demonstrate ICS responsiveness and clinical benefit on electronically monitored treatment with standard high-dose ICS and long-acting β2-agonist treatment. MEASUREMENTS AND MAIN RESULTS: Clinical response was assessed using the Asthma Control Questionnaire-5, spirometry, and biomarker measurements (FeNO and peripheral blood eosinophil count). Of 250 subjects, 201 completed the test with 130 positive suppression tests. Compared with a negative suppression test, a positive test identified a FeNO-low population when adherent with ICS/long-acting β2-agonist (median, 26 ppb [interquartile range, 16-36 ppb] vs. 43 ppb [interquartile range, 38-73 ppb]) with significantly greater FEV1% (mean, 88.2 ± 16.4 vs. 74.1 ± 20.9; P < 0.01). Asthma Control Questionnaire-5 improved significantly in both groups (positive test: mean difference, -1.2; 95% confidence interval, -0.9 to -1.5; negative test: mean difference, -0.9; 95% confidence interval, -0.4 to -1.3). CONCLUSIONS: Remote FeNO suppression testing is an effective means of identifying nonadherence to ICS in subjects with difficult-to-control asthma and the substantial population of subjects who derive important clinical benefits from optimized ICS/long-acting β2-agonist treatment.
Authors: Orla O'Carroll; Rachel MacCann; Aoife O'Reilly; Eleanor M Dunican; Eoin R Feeney; Silke Ryan; Aoife Cotter; Patrick W Mallon; Michael P Keane; Marcus W Butler; Cormac McCarthy Journal: Eur Respir J Date: 2020-08-13 Impact factor: 16.671
Authors: Alison Moore; Andrew Preece; Raj Sharma; Liam G Heaney; Richard W Costello; Robert A Wise; Andrea Ludwig-Sengpiel; Giselle Mosnaim; Jamie Rees; Ryan Tomlinson; Ruth Tal-Singer; David A Stempel; Neil Barnes Journal: Eur Respir J Date: 2021-06-04 Impact factor: 33.795
Authors: Evalyne M Jansen; Susanne J van de Hei; Boudewijn J H Dierick; Huib A M Kerstjens; Janwillem W H Kocks; Job F M van Boven Journal: J Thorac Dis Date: 2021-06 Impact factor: 2.895